is that Zytiga will be coming off patent at just about the time we would expect, if all goes well, ARN-509 would be launched," said Paul Cleveland, chief financial officer for San Diego-based Aragon, a company with 40 employees that was founded less than four years ago

The new cash is expected to let San Diego-based Mast reach top-line data, said Brandi Roberts, chief financial officer, although it "probably won't get us through filing the new drug application and getting ready for commercialization

Filing its S-1 as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, the San Diego-based firm is seeking to raise up to $69 million to continue the clinical development of emricasan, a pan-caspase inhibitor

It's much more important to show me how you can compete and how much of the market you can penetrate," Neil Berkley, director of business development at San Diego-based Cadence Pharmaceuticals Inc., told the audience...When San Diego-based Orexigen Therapeutics Inc

San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

Based on a 31.5 percent royalty, Tenthoff's estimates San Diego-based Arena would earn about $22 million this year in addition to $65 million in launch milestones that Eisai owes the company

San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

Metreleptin, a recombinant analogue of human hormone leptin, was developed by San Diego-based Amylin Pharmaceuticals Inc., which was acquired in a joint buyout by BMS and AstraZeneca last year. (See BioWorld Today, July 3, 2012

Modest Offering 'Evokes' Public Market Access San Diego-based Evoke Pharma has stayed out of the limelight, advancing a single asset with just two full-time employees

Although any ADC failure in the clinic – especially in Phase III – is a major disappointment for the sponsor and patients, the result should not handicap ADC development, said Lawson Macartney, CEO of San Diego-based Ambrx Inc., which has inked a stunning strand of ADC deals with pharma partners. (See BioWorld Today, June 19, 2012, April 8, 2013, and May 6, 2013.) While acknowledging that he had no detailed knowledge about the trial design and could only speculate on the suboptimal efficacy

In addition to the trio of filings, one biotech IPO closed last week, as San Diego-based Ambit Biosciences Corp

Phase I/II data reported by San Diego-based TargeGen prior to the Sanofi buyout also showed the potential of SAR302503 to reduce white blood cell count in patients with leukocytosis and reduce mutant cells responsible for causing the disease in about two-thirds of the patients treated

The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million

On completion of the transaction, which is due to happen Wednesday, Cosmo will retain almost 3 million Santarus shares, representing 4.63 percent of the San Diego-based firm's stock

On completion of the transaction, which is due to happen Wednesday, Cosmo will retain almost 3 million Santarus shares, representing 4.63 percent of the San Diego-based firm's stock

These studies should read out in the second half of next year, and the funding will take us through the end of 2014," said Mike Grey, president and CEO of San Diego-based Lumena

I think it is based on the relationship we've built with BMS, but this is a different franchise area, a different portion of our technology platform," said Simon Allen, chief business officer of San Diego-based Ambrx

were down nearly 10 percent Friday following Thursday's after-market release of first-quarter earnings, which included news that the San Diego-based biotech is pulling its European marketing application for obesity drug Belviq (lorcaserin), though the bigger disappointment may be the ongoing delay in Belviq's U.S

San Diego-based Abide's platform involves proteomic technology from the Scripps Research Institute